Nkarta (NKTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with voting available online until June 9, 2026.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of two directors to serve until the 2029 annual meeting: Ali Behbahani, M.D., M.B.A., and Zachary Scheiner, Ph.D.
Ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Advisory approval of executive compensation as disclosed in the proxy statement.
Advisory vote on the frequency of future say-on-pay votes, with the board recommending every 1 year.
Proxies may vote on other business that arises at the meeting.
Board of directors and corporate governance
Board recommends the election of two directors for multi-year terms, ensuring continuity in governance.
Latest events from Nkarta
- Board recommends approval of all proxy proposals, with strong governance and compensation oversight.NKTX
Proxy filing23 Apr 2026 - Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway.NKTX
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Biotech seeks up to $350M for NK cell therapy pipeline, with $100M ATM via Stifel.NKTX
Registration filing25 Mar 2026 - Dose escalation advanced in clinical trials; cash runway extends into 2029.NKTX
Q4 202525 Mar 2026 - Focused on CD19 NK cell therapy for autoimmune disease, advancing toward pivotal trials and outpatient care.NKTX
Leerink Global Healthcare Conference 202610 Mar 2026 - Allogeneic NK cell therapy advances with strong safety, pivotal data expected this year.NKTX
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Allogeneic CAR NK therapy advances in autoimmune diseases, with key data expected in 2025.NKTX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Leading allogeneic NK cell trials in autoimmune disease, prioritizing safety and drug-free remission.NKTX
Stifel 2024 Healthcare Conference13 Jan 2026 - Robust, safe, off-the-shelf NK cell therapy targets I&I with key data expected in 2025.NKTX
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026